The target of a biotherapeutic can interfere in the detection of anti-drug antibodies (ADA). The presence of target in samples, especially targets that exist as a multimer in solution, can cause false positives in the standard bridging assay format
for ADA. Although not always straightforward, it can be addressed and mitigated in a properly designed immunoassay with sample pre-treatment. This webinar will give an overview of the different types of interferences, and current methodologies
and approaches being utilized to resolve or reduce them.
- Overview of the bridging assay format
- Things to look for to determine if target interference may be a problem
- How to create a false positive
- Methods to mitigate target interference
Jim McNally, PhD
Chief Scientific Officer
Dr. Jim McNally has an extensive background in bioanalytical assay development and program leadership spanning nearly 20 years working in the pharmaceutical and biotechnology industry. Prior to joining BioAgilytix, Dr. McNally held roles at CRISPR
Therapeutics, Genzyme, Pfizer, EMD Serono, and Shire which have given him broad experience in the development of large molecule, gene therapy, and cell therapy biotherapeutics.
Dr. McNally is a recognized thought leader in the development and application of bioanalytical methods used in regulatory submissions and is specifically skilled in progression of biotherapeutics from research through clinical development. He
has a special interest in the immunogenicity of biotherapeutics and leads an industry-wide working group to address this issue. A key part of his role at BioAgilytix is advising on emerging scientific developments and providing scientific
and regulatory guidance.
Cost: No Cost!